OmicXHealth

Pre-seed startup developing non-invasive early cancer detection tests using AI/ML analysis of circulating cell-free DNA (cfDNA) methylation. The team builds bioinformatics pipelines and machine learning models trained on bisulfite-sequenced datasets and limited clinical samples, and is progressing toward CLIA Laboratory Developed Test (LDT) validation and clinical pilot studies. Recent milestones include external sequencing collaborations, a patent filing for a "sequence once, analyze many times" software-driven approach, conference presentations, and selection to an accelerator program.